Fut, nem toboroz1. fázis
A Phase 1b study to evaluate the safety, pharmacokinetics, and anti-tumour activity of the Myc inhibitor OMO-103 administered intravenously in combination with different drugs in patients with advanced solid tumours
Key facts
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Santander és Zaragoza, SpanyolországSee the 6 sites
- Phase
- 1. fázis
Where in Spanyolország
- Hospital Universitari Vall d'HebronBarcelona, SpanyolországNo longer taking part
- Institut Catala D'oncologiaL'Hospitalet de Llobregat, SpanyolországNo longer taking part
- Hospital General Universitario Gregorio MarañónMadrid, SpanyolországNo longer taking part
- Hospital Universitario Regional de MálagaMálaga, SpanyolországNo longer taking part
- Hospital Universitario Marqués de ValdecillaSantander, SpanyolországNo longer taking part
- Hospital Unviersitario Miguel ServetZaragoza, SpanyolországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peptomyc S.L.
- Trial code
- EU 2023-504376-21-00
- Record updated
- 2026. szeptember 8.